• / Free eNewsletters & Magazine
  • / My Account
Home>Research and Markets: Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Pipeline Review 2015 - Analysis of 53 Companies & 78 Drug Profiles

Research and Markets: Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Pipeline Review 2015 - Analysis of 53 Companies & 78 Drug Profiles

3party Content

Thu, 5 Mar 2015

Research and Markets: Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Pipeline Review 2015 - Analysis of 53 Companies & 78 Drug Profiles
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.